Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MATRIX-RICE Plus Transplant Looks Effective in Poor Prognosis DLBCL Group

Publish date:: January 3, 2020

Key clinical point: The combination of MATRIX-RICE chemotherapy plus autologous transplant appears effective in patients with diffuse large B-cell lymphoma and secondary central nervous system (CNS) dissemination.

Major finding: At 1 year, the trial met a pre-specified threshold for progression-free survival.

Study details: A phase 2 trial enrolling 79 patients with diffuse large B-cell lymphoma and CNS involvement.

Disclosures: Dr. Ferreri reported disclosures related to Celgene, Gilead, Novartis, and Roche.

Citation:

Ferreri AJM et al. ASH 2019, Abstract 353.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,